Catalog #SIM0090
InVivoSIM anti-human CD20 (Ocrelizumab Biosimilar)
Clone
Ocrelizumab
Reactivities
Human
Isotype
Human IgG1, κ
Product Description
This non‑therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Ocrelizumab, making it ideal for research use. Ocrelizumab is a humanized IgG1 monoclonal antibody that specifically targets CD20, a surface antigen expressed on pre-B and mature B cells but absent on stem cells and plasma cells. CD20 plays a key role in B cell activation and proliferation. By binding to CD20, Ocrelizumab mediates B cell depletion primarily through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). This Ocrelizumab biosimilar is well suited for investigating B cell–mediated mechanisms in autoimmunity, neuroinflammation, and hematologic malignancies, as well as for exploring therapeutic B cell depletion strategies.
Specifications
| Isotype | Human IgG1, κ |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Immunogen | Human CD20 |
| Reported Applications |
In vivo functional assays in vitro functional assays Flow cytometry ELISA |
| Formulation |
pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL gel clotting assay |
| Purity |
≥95% Determined by SDS-PAGE |
| Sterility | 0.2 µm filtration |
| Production | Purified from cell culture supernatant in an animal-free facility |
| Purification | Protein A |
| Molecular Weight | 150 kDa |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| Need a Custom Formulation? | See All Antibody Customization Options |